Argyle Capital Partners’s Johnson & Johnson JNJ Stock Holding History

Argyle Capital Partners’s Portfolio JNJ Stock Details JNJ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,255	Closed	-$233K	–	162
2025 Q3	$233K	Buy	+1,255	New	+$215K	0.17%	146

Other funds holding JNJ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Argyle Capital Partners's JNJ Position: Q4 2025 in Review

Argyle Capital Partners sold out of Johnson & Johnson (JNJ) in Q4 2025, closing a stake of 1,255 shares — an estimated $233K sold.

Argyle Capital Partners first reported a position in JNJ in Q3 2025 and held it in 1 quarter. The position peaked at $233K in Q3 2025. 4,520 funds tracked by Wall St. Rank hold JNJ as of Q4 2025.

Argyle Capital Partners reported no remaining Johnson & Johnson position as of Q4 2025 after selling out during the quarter.
Argyle Capital Partners sold 1,255 Johnson & Johnson shares in Q4 2025, an estimated $233K.
Argyle Capital Partners first reported a position in Johnson & Johnson in Q3 2025 and held it in 1 quarter.
Argyle Capital Partners's Johnson & Johnson position peaked at $233K in Q3 2025.
4,520 funds tracked by Wall St. Rank held Johnson & Johnson as of Q4 2025.

Based on Argyle Capital Partners's 13F filing for Q4 2025, filed 17 Feb 2026.